CompoAtlas

Sedivitax Calmstress Advanced

Food supplement declared in France

Sedivitax Calmstress Advanced is a food supplement declared in France. Status: earlier declaration, replaced by the 2025 declaration. None of the rules we check flags an issue with its declared composition.

Brand
not provided
Food business operator placing the product on the market
Aboca S.P.A. Società Agricola
Status
Earlier declaration, replaced by the 2025 declaration : Sedivitax Calmstress Advanced
Form
Gélule
Daily dose
3 gélules
Directions for use
Il est conseillé de prendre 2 à 3 gélules au cours de la journée. À partir de 12 ans.
Intended populations
Hommes et femmes de 18 ans et plus
Not recommended for (according to the manufacturer)
Adolescents (moins de 18 ans), Femmes allaitantes, Enfants (moins de 12 ans), Enfants en bas âge (1 à 3 ans), Femmes enceintes, Nourrissons (moins de 1 an), Sous traitement médicamenteux, Enfants (de moins de 6 ans), Enfants (de moins de 10 ans)
Objectives stated by the manufacturer (these are not authorised claims)
Système nerveux

Declaration 339069, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 23 October 2026.

Regulatory points

None of the rules we check applies to the declared ingredients.

Declared composition

Plants

PlantPartPreparationPer day
Passiflora incarnata L.FeuillePoudre (de plantes séchées ou broyées)668 mg
Passiflora incarnata L.FeuilleExtrait sec hydroalcoolique173 mg
Crataegus monogyna Jacq.Sommités fleuriesExtrait sec hydroalcoolique138 mg
Matricaria chamomilla L.FleurExtrait sec hydroalcoolique92 mg
Ziziphus jujuba Mill.GraineExtrait sec hydroalcoolique58 mg
Salvia officinalis subsp. lavandulifolia (Vahl) GamsEssence (feuille)Distillation23 mg

Other ingredients

gélatine

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Label warnings

Ne pas dépasser les doses conseillées. Les compléments alimentaires ne constituent pas une substitution à une alimentation variée et équilibrée et doivent être utilisés dans le cadre d’un style de vie sain. Le produit doit être conservé hors de portée des enfants. PRÉCAUTIONS D’EMPLOI : le produit est réservé aux adultes. Déconseillé aux femmes enceintes et allaitantes. Déconseillé en cas d'allergie croisée connue, en particulier aux plantes de la famille des Asteraceae. En cas de traitements médicamenteux, demander conseil à un professionel de santé

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Passiflora incarnata L.
    Read the warning, when it applies and the studies cited

    PASSIONFLOWER -PASSIFLORA INCARNATA

    Route of administration: Oral

    Cautions and warnings

    Condition of application: Sleep aid.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists for more than 4 weeks (chronic insomnia) (Berardi et al. 2002: DiPiro et al. 2002).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: Restlessness/nervousness.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: All uses.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2014).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product avoid taking with alcohol or products that cause drowsiness (EMA 2014; Brinker 2010).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness (EMA 2014).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (EMA 2014).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 29 November 2024

  • Crataegus monogyna Jacq.
    Read the warning, when it applies and the studies cited

    Hawthorn

    Route of administration: Oral (ESCOP 2009; Bradley 2006; Mills and Bone 2000)

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking cardiac glycosides (e.g., digoxin) or blood pressure or heart medications (Brinker 2010; Bradley 2006).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have chest pain, irregular heartbeat, or shortness of breath.

    Health Canada monograph dated 31 July 2026

  • Matricaria chamomilla L.
    Read the warning, when it applies and the studies cited

    GERMAN CHAMOMILE - MATRICARIA CHAMOMILLA Oral

    Route of administration: Oral (ESCOP 2003; Blumenthal et al. 2000; WHO 1999; Bradley 1992).

    Cautions and warnings

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (ESCOP 2003; Bradley 1992).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 19 December 2025

    German Chamomile - Matricaria Chamomilla Topical

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (ESCOP 2003; Bradley 1992).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 31 January 2025

    GERMAN CHAMOMILE - MATRICARIA CHAMOMILLA Buccal

    Route of administration: Buccal (ESCOP 2003; Blumenthal et al. 2000; Bradley 1992)

    Cautions and warnings

    Ask a healthcare practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (ESCOP 2003; Bradley 1992).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 29 May 2026

  • Salvia officinalis subsp. lavandulifolia (Vahl) Gams
    Read the warning, when it applies and the studies cited

    SAGE - SALVIA OFFICINALIS - Buccal

    Cautions and warnings

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or last (for) more than 7 days.

    Health Canada monograph dated 28 March 2025

    SAGE -SALVIA OFFICINALIS Oral

    Cautions and warnings

    Condition of application: Carminative, Diaphoretic, Antihidrotic, Antigalactagogue.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Contraindications

    Condition of application: All products.

    Do not use if you are pregnant or breastfeeding (Gardner and McGuffin 2013; Bradley 2006; Mills and Bone 2005).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Do not use if you have a seizure disorder such as epilepsy (Gardner and McGuffin 2013; Bradley 2006; Mills and Bone 2005).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 10 January 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Other declarations with the same name

In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Enter to analyse, Shift+Enter for a new line